drugset

drugset / Trial / NCT06656351

B-FREE Chronic Babesiosis Study

NCT06656351 ↗

Phase 2 Recruiting 40 enrolled 60 Degrees Pharmaceuticals LLC

NaSingle-groupOpen-labelTreatment

Summary

Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Timeline

Start: 2025-11-18
Primary completion: 2027-02
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tafenoquine	Small molecule	200 mg	Oral

Indications